Use of GLP-1 analogues for the treatment of disorders associated with dysfunctional synaptic transmission
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Jun 23, 2015
Grant Date -
Sep 9, 2010
app pub date -
Sep 8, 2008
filing date -
Sep 7, 2007
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
The present invention relates to a peptide analogue of glucagon-like peptide-1 (7-36), which is useful to prophylactically prevent, improve, or reverse the diminished cognitive function associated with these types of disorders, by increasing (or sustaining) the LTP of synaptic transmission. Moreover, sustaining LTP may find utility in the prophylaxis of neurological disease by delaying the onset of impaired cognitive processes, and could serve as a treatment, not only for the diminished cognitive function caused by neurodegeneration, but also for the dysfunctional cognitive processes associated with trauma or age.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully